share_log

POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

POS AM：修改注册声明表
美股SEC公告 ·  10/01 18:08

Moomoo AI 已提取核心信息

NeuroSense Therapeutics Ltd. (NeuroSense), a clinical-stage biotechnology company, has filed a post-effective amendment to its Form F-1 registration statement with the U.S. Securities and Exchange Commission (SEC) on September 30, 2024. The amendment relates to the registration of 3,000,000 ordinary shares and an equal number of warrants to purchase additional shares at a price of $1.50 per share. These securities were initially issued in private placements in June 2023 and April 2024, and the warrants are exercisable until June 2028 and April 2029, respectively. The registration also includes 70,964 ordinary shares issued to a placement agent as partial consideration for services related to the April 2024 offering. The registration allows the selling shareholders to offer these securities publicly, and the company will not receive any proceeds from the sales. NeuroSense's ordinary shares are listed on The Nasdaq Capital Market under the symbol 'NRSN'.
NeuroSense Therapeutics Ltd. (NeuroSense), a clinical-stage biotechnology company, has filed a post-effective amendment to its Form F-1 registration statement with the U.S. Securities and Exchange Commission (SEC) on September 30, 2024. The amendment relates to the registration of 3,000,000 ordinary shares and an equal number of warrants to purchase additional shares at a price of $1.50 per share. These securities were initially issued in private placements in June 2023 and April 2024, and the warrants are exercisable until June 2028 and April 2029, respectively. The registration also includes 70,964 ordinary shares issued to a placement agent as partial consideration for services related to the April 2024 offering. The registration allows the selling shareholders to offer these securities publicly, and the company will not receive any proceeds from the sales. NeuroSense's ordinary shares are listed on The Nasdaq Capital Market under the symbol 'NRSN'.
NeuroSense Therapeutics Ltd.（NeuroSense）是一家处于临床阶段的生物技术公司，于2024年9月30日向美国证券交易委员会（SEC）提交了一份Form F-1登记声明的后有效修正。修正涉及注册300万普通股和相同数量的权证，以每股1.50美元的价格购买额外股份。这些证券最初是在2023年6月和2024年4月以私下配售方式发行的，而权证可在2028年6月和2029年4月之前行使。登记中还包括在2024年4月募资活动中向一家配售代理发行的70,964股普通股作为相关服务的部分补偿。登记允许出售股东公开提供这些证券，公司将不会从销售中获得任何收益。NeuroSense的普通股在纳斯达克资本市场上以“NRSN”标的上市。
NeuroSense Therapeutics Ltd.（NeuroSense）是一家处于临床阶段的生物技术公司，于2024年9月30日向美国证券交易委员会（SEC）提交了一份Form F-1登记声明的后有效修正。修正涉及注册300万普通股和相同数量的权证，以每股1.50美元的价格购买额外股份。这些证券最初是在2023年6月和2024年4月以私下配售方式发行的，而权证可在2028年6月和2029年4月之前行使。登记中还包括在2024年4月募资活动中向一家配售代理发行的70,964股普通股作为相关服务的部分补偿。登记允许出售股东公开提供这些证券，公司将不会从销售中获得任何收益。NeuroSense的普通股在纳斯达克资本市场上以“NRSN”标的上市。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间